Dr. John Cush RheumNow
2 years 10 months ago
RA pts more likely to get autoimmune thyroid Dz (AITD), but after dx, AITD risk signif. drops (HR 0.81), suggesting RA Rx lowers AITD risk; greater drop in biologic Rx RA (HR 0.54).Swiss registry compared 13,731 new-onset RA pts to 63,201 matched controls https://t.co/n0n2EfUyqR https://t.co/yMMHvYRsyY
Dr. John Cush RheumNow
2 years 10 months ago
Cannabis Use in Rheumatic Diseases
Dr. Janet Pope discusses several abstracts presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/C2vbbERoHZ https://t.co/XeiS0cJjuy
Dr. John Cush RheumNow
2 years 10 months ago
INVIGORATE-1 Study: IV Secukinumab for Treatment of Active axSpA
Dr. Atul Deodhar reports on abstract 2545 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/Fhv7dhDTJA https://t.co/Zz0PwFjOD4
Dr. John Cush RheumNow
2 years 10 months ago
CDC: Chronic Fatigue Syndrome 2021-2022
The current CDC report estimates that 1.3% of adults had myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), based on the most recent population based National Health Interview Survey (NHIS 2021–2022).
https://t.co/4LeQ7DJPyI https://t.co/5ITG46d25M
Dr. John Cush RheumNow
2 years 10 months ago
ICYMI: Cancer and TNF inhibitors
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions.
https://t.co/rNSTcT5O6L https://t.co/f5lvMTH7ik
Over the years of navigating the annual meeting, I found the sessions with the most impact to my practice were the Plenary Sessions. During these sessions, the latest research is presented, new ideas are floated, and old myths debunked. Here are the top ACR2023 Plenary abstracts I found impactful for my practice.
Pregnant women with autoimmune rheumatic diseases (ARDs) and antiphospholipid syndrome (APS) face significantly increased risks of cardiovascular events (CVEs). This increased risk is often attributed to ARDs, its medications or comorbidities associated with it.
Dr. John Cush RheumNow
2 years 10 months ago
The ARGO Project for Rheumatology Fellows
Dr. Sheila Reyes (Philippines) talks with Dr. Lisa Traboco about abstract 2078, presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/RRjc38JpEQ https://t.co/q9rCxbWzNh
Fatigue is highly prevalent in inflammatory rheumatic and musculoskeletal diseases (I-RMDs) patients, is often unaddressed and yet it has significant effects on patient quality of life. A EULAR task force set out to develop recommendations for the management of fatigue in people with I-RMDs.
Dr. John Cush RheumNow
2 years 10 months ago
When should we be starting therapy in GCA and PMR?
The problem with having therapies that work is that you then have to figure out what to do with them. You cannot hide behind the ambiguity of therapeutic inadequacy.
https://t.co/oRWTeH5Q9h https://t.co/BbswdffoKM
Dr. John Cush RheumNow
2 years 10 months ago
Save the date for RheumNow Live 2024, on January 27-28, in Dallas, TX, or from the comfort of your own space through our virtual platform!
Why choose RheumNow Live? Because this isn't just another conference – it's a revolution in medical education!
https://t.co/K2YYqjjs8F https://t.co/MinRm9N9rz
Dr. John Cush RheumNow
2 years 10 months ago
Health disparities in SLE reviewed disparities by Parodis et al. Racial and ethnic influences on manifestations and outcomes reviewed, along with common pitfalls in studies, along w/ proposed framework for research on health disparities in SLE (full read) https://t.co/7GvzttR9HZ https://t.co/wYGiMg4zqK
Dr. John Cush RheumNow
2 years 10 months ago
Promising Therapies for Sjogren's
Dr. Yuz Yusof discusses abstracts 1634 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/8iSDMKtKwa https://t.co/QCYTnpYKFN
